Nova Anchora
Developing a corrective topical biologic therapy for Dystrophic Epidermolysis Bullosa (DEB)
An Overview of DEB
DEB is a rare, genetic skin disease — a particularly debilitating form of Epidermolysis Bullosa (EB), which is sometimes called “butterfly disease” due to the fragility of patients’ skin (similar to butterfly’s wings).
In affected individuals, collagen VII (C7) — a protein that forms “anchoring fibrils” that attach the skin’s outer protective layer (epidermis) — is not functioning correctly. As a result, even light rubbing of the skin can cause blistering or tearing, frequently causing open wounds to form and persist.
Nova Anchora’s approach
Nova Anchora is advancing NvA-011, an investigative therapeutic gel designed to apply to patients’ wounds during normal bandage changes. NvA-011 contains a genetically corrected version of C7, manufactured with proprietary technology licensed from Stanford University designed to enhance its stability.
In relation to existing approved treatments, NvA-011 is being developed to, in particular, address treatment gaps and enhance ease-of-use.
Current development status
Nova Anchora has received Pre-IND feedback from the FDA, and is initiating studies that enable clinical trials. The FDA has also granted Nova Anchora Orphan Drug and Rare Pediatric special designations.
Company leadership
-
Jason Bhardwaj
CEO, Co-Founder
20+ years in healthcare and biotech leadership; Duke Biomedical B.S.E., Harvard M.B.A. Previously CEO Follica (Derm Pre-IND to Ph3-ready); Tal Medical, Medtronic, Bain & Company
-
Dr. Peter Marinkovich
Chair of SAB, Co-Founder
Associate Professor of Dermatology at Stanford, Faculty of Epithelial Biology and Cancer Biology. Key Opinion Leader in the EB field. Primary investigator for several clinical programs, including Vyjuvek (B-VEC) for Krystal Bio
